Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

iCANSleep: Smartphone App-Based Insomnia Treatment for Cancer Survivors

for
Insomnia, Cancer
Location: St. John's
Sponsor: Memorial University of Newfoundland

Sex: All

Age: 18+

Code: NCT07101302

Recruiting
Active & Responsive

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

for
Solid Tumor
Location: New Haven CT, Charleston SC, Denver CO, Portland OR
Sponsor: Axcynsis Therapeutics Pte Ltd

Sex: All

Age: 18+

Code: NCT06809114

Phase 1, Recruiting
Active & Responsive

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

for
Malignant Neoplasm
Location: Quebec, New Brunswick NJ, Montreal, Fairfax VA, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07247110

Phase 1, Recruiting
Active & Responsive

Study of PAT in Patients With Solid Tumor Cancers

for
Metastasis, Solid Tumor
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 18+

Code: NCT05338658

Phase 1, Recruiting
Active & Responsive

The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes

for
Insulin Dependent Diabetes Mellitus,
Location: Montreal
Sponsor: McGill University

Sex: All

Age: 12+

Code: NCT07348432

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 18+

Code: NCT06414278

Recruiting
Active & Responsive

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

for
Advanced Solid Cancers
Location: New York NY, Orlando FL, Detroit MI, Denver CO
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07186842

Phase 1, Phase 2, Recruiting
Active & Responsive

The Florida ASCENT Study

for
Cancer, Food Deprivation, Food Habits, Food Selection,
Location: Gainesville FL
Sponsor: University of Florida

Sex: All

Age: 18 - 70+

Code: NCT07042243

Recruiting
Active & Responsive

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

for
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Location: New Haven CT, Philadelphia PA, Fairfax VA,
Sponsor: Ipsen

Sex: All

Age: 18+

Code: NCT07213817

Phase 1, Phase 2, Recruiting
Active & Responsive

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

for
Malignant Neoplasm
Location: Clermont FL, Fargo ND, Sioux Falls SD
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07252739

Phase 2, Recruiting
Active & Responsive

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

for
Advanced Solid Tumor, Metastatic Solid Tumor
Location: Toronto, Grand Rapids MI, Nashville TN, Houston TX,
Sponsor: Ipsen

Sex: All

Age: 18+

Code: NCT07213830

Phase 1, Phase 2, Recruiting
Active & Responsive

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

for
Metastatic Solid Tumors, Stage 4 Cancer
Location: Rochester MN
Sponsor: New Phase Ltd.

Sex: All

Age: 18+

Code: NCT07224464

Recruiting
Active & Responsive

A Study of DS3610a in Participants With Advanced Solid Tumor

for
Solid Tumors, Metastatic Solid Tumors
Location: Milwaukee WI
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT07159126

Phase 1, Recruiting
Active & Responsive

A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3

for
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Location: Baltimore MD, Fairfax VA, Sarasota FL, Atlanta GA,
Sponsor: Myricx Pharma Limited

Sex: All

Age: 18+

Code: NCT07807241

Phase 1, Recruiting
Active & Responsive

Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

for
Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma,
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital

Sex: All

Age: 0+

Code: NCT07514819

Recruiting
Active & Responsive

Feasibility Study of a Guided Imagery Therapy Mobile Application for Functional Abdominal Pain Disorders in Children

for
Functional Abdominal Pain Disorders,
Location: Houston TX, Austin TX
Sponsor: Baylor College of Medicine

Sex: All

Age: 7 - 12

Code: NCT07222943

Recruiting
Active & Responsive

Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)

for
Solid Tumors
Location: Lexington KY
Sponsor: Val Adams

Sex: All

Age: 18 - 70+

Code: NCT07661459

Phase 2, Recruiting
Active & Responsive

A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

for
Solid Tumors
Location: New York NY, Baltimore MD, Atlanta GA, Houston TX
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07492680

Phase 2, Recruiting
Active & Responsive

Telehealth Music Therapy for Adults With Endocrine Disorder and Depression

for
Type 1 Diabetes, Hashimoto Disease, Graves Disease,
Location: Boone NC
Sponsor: Appalachian State University

Sex: All

Age: 18 - 65

Code: NCT07413874

Recruiting
Active & Responsive

Capturing Food Intake in Patients Undergoing Radiation Therapy for Cancer

for
Cancer, Radiation Therapy, Dietary Intake
Location: Minneapolis MN
Sponsor: University of Minnesota

Sex: All

Age: 18+

Code: NCT07682714

Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial